Nutrition Clinical Trial
Official title:
A Randomized Cross-over Study of The Digestion of Protein Powders in Healthy Participants Using SIMBA and LIMBA Capsule
Verified date | April 2024 |
Source | Nimble Science Ltd. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study aims to understand how the Milk Protein Concentrate/Fast Protein (MCP/FP) investigational product (IP) compares to a control the Micellar Casein Isolate/Slow Protein (MCI/SP) product in healthy volunteers. It involves two phases where participants will try both products. The main goal is to measure the type and rate of amino acids quickly in the small intestine after consuming the protein products and how this relates to gastric emptying.
Status | Not yet recruiting |
Enrollment | 20 |
Est. completion date | August 20, 2024 |
Est. primary completion date | August 12, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 20 Years to 45 Years |
Eligibility | Inclusion Criteria: 1. Aged 20 to 45 years old at inclusion in the study, both female and male subjects. 2. Signed Informed Consent; willing & able to comply with study procedures. 3. Willing to maintain their diet and physical activity levels during the study. 4. Able to swallow a size-00 capsule (23mm length). 5. No planned change in diet or medical interventions during the study duration Exclusion Criteria: 1. Use of regular prescription medications, including antihypertensives, anti-inflammatory drugs, corticosteroids, immunosuppressants, antidepressants, antipsychotics, anti-diabetic medications, and anti-arrhythmic agents, which in the opinion of the investigator, would adversely affect study safety or outcome. 2. Prior gastrointestinal disease, surgery, or radiation treatment which, in the Investigator's opinion, would lead to intestinal structuring or obstruction with a risk of capsule non-excretion, including, e.g., achalasia, eosinophilic esophagitis, cancer diagnosis or previous esophageal, gastric, small intestinal, or colonic surgery. Appendectomy or cholecystectomy more than 3 months before the screening visit is acceptable. 3. History of known structural gastrointestinal abnormalities such as structures or fistulas leading to mechanical obstruction. 4. Known history abdominal radiation treatment. 5. Use of any medications in the week prior to the screening study visit, unless part of regular treatment, that could substantially alter gastrointestinal motor function (e.g., opioids, prokinetics, anticholinergics, GLP-1 analogues); laxative use is allowed if it is kept unchanged in the week prior to the study visit. Proton pump inhibitors (PPIs) are allowed provided a wash-out period of 48 hours is respected before swallowing the SIMBA/LIMBA capsules and PPI treatment is resumed only 4 hours thereafter. 6. Organic motility disorder, including gastroparesis, intestinal pseudo-obstruction, systemic sclerosis, Ogilvie's syndrome. 7. Any significant gastrointestinal, heart, liver, lung, kidney, blood, endocrine or nervous system disease, which in the opinion of the investigator, would adversely affect study safety or outcome. 8. Cancer diagnosis or treatment within the past year (non-melanoma skin cancers are acceptable). 9. History or diagnosis of immunological or infectious disease (hepatitis, tuberculosis, HIV, Parkinson's). 10. History of oropharyngeal dysphagia, or other swallowing disorder with a risk of capsule aspiration. 11. Antibiotic use (except for topical use) = 12 weeks prior to screening. Potential participants may be eligible once a 12-week washout is completed. 12. Consumption of probiotic or prebiotic supplements within 1 month prior to screening. Potential participants may be eligible once a 1-month washout is completed. 13. Any prior Fecal Microbiota Transplantation. 14. Colon cleanses/bowel prep for 2 weeks 15. Pregnant or breastfeeding. 16. Planning to become pregnant. 17. Alcohol or drug abuse. 18. Milk or soy allergy 19. Lactose intolerant 20. Vegan diet |
Country | Name | City | State |
---|---|---|---|
Canada | Cumming School of Medicine | Calgary | Alberta |
Lead Sponsor | Collaborator |
---|---|
Nimble Science Ltd. |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Time to presentation of the peptides in the small intestine by SIMBA/LIMBA capsule | Time to presentation of IP or Control peptides to the small intestine compared within subjects, measured by proteomic analysis from SIMBA/LIMBA capsules located in the small intestine based on X-ray confirmation. eg. T-90 min IP vs T-90 min Control, T-60 min IP vs T-60 min Control, etc), | From 0 minute to 240 minutes after ingestion of the capsule per intervention period | |
Secondary | Time to presentation of the peptides in the small intestine by blood analysis | Time to presentation of IP or Control peptides to the small intestine compared within subjects, measured by total amino acid analysis from blood samples difference in small intestinal proteomic profile between IP and Control phases based on PCA plot. (Maximum difference is defined by comparing the various SIMBA/LIMBA capsules within each patient, eg. T-90 min IP vs T-90 min Control, T-60 min IP vs T-60 min Control, etc), | From 0 minute to 240 minutes after ingestion of the protein product | |
Secondary | Determination of peptide composition | The composition of milk-derived peptides by proteomic analysis. Statistical and mathematical analyses be employed to characterize the peptide profiles. | From 0 minute to 240 minutes after ingestion of the protein product per intervention period | |
Secondary | Determination of proteolysis rate | The rate of milk-derived peptide proteolysis, gastric emptying, and nutrient absorption of IP or Control peptides. Statistical and mathematical analyses be employed to discern correlations and causative relationships among these processes. | From 0 minute to 240 minutes after ingestion of the protein product per intervention period | |
Secondary | Determination of metabolites from various samples | The presence of the milk-derived peptide metabolites in small intestine, feces, and blood samples, following the IP or control intervention. Method of analysis being metabolomic technology. | From 0 minute to 240 minutes after ingestion of the capsule per intervention period | |
Secondary | Characterization of microbiota composition by metagenomic analysis | Qualitative investigation of gut bacteria participation in the metabolism of dietary proteins, influencing the breakdown of peptides and amino acids during digestion, based on microbiome profiles compared across subjects. | From 0 minute to 240 minutes after ingestion of the capsule per intervention period |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05934318 -
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
|
N/A | |
Recruiting |
NCT05867433 -
Strong Teens for Healthy Schools Change Club: A Civic Engagement Approach to Improving Physical Activity and Healthy Eating Environments
|
N/A | |
Completed |
NCT02376530 -
Price Changes and Nutrient Profiling Among Adult Grocery Shoppers
|
N/A | |
Completed |
NCT01040975 -
Teen CHAT: Improving Physician Communication With Adolescents About Healthy Weight
|
N/A | |
Completed |
NCT00957814 -
Nutritional Orientations and Adherence, Nutritional Status, Clinical and Life Quality Parameters of Heart Failure (HF) Patients
|
N/A | |
Completed |
NCT00808756 -
Study on Fermentable Carbohydrates in Healthy Infants
|
N/A | |
Completed |
NCT03290118 -
The Efficacy of Front-of-package Labelling Schemes: an Experimental Study
|
N/A | |
Completed |
NCT03575884 -
Fit 5 Kids Screen Time Reduction Curriculum for Latino Preschoolers
|
N/A | |
Completed |
NCT03963778 -
Organisational Culture and Nutritional Care
|
||
Completed |
NCT05633251 -
Using Reinforcement Schedules to Increase Fruit&Vegetable Intake, Reduce Waste, and Increase School Lunch Participation
|
N/A | |
Recruiting |
NCT05977959 -
Optimizing the Impact of the Healthy School Recognized Campus Program on Youth's CVD Risk Factors
|
N/A | |
Recruiting |
NCT05138276 -
Effect of Autologous Cord Blood Mononuclear Cells for Digestive System in Preterm Neonates
|
Early Phase 1 | |
Completed |
NCT03906851 -
Active and Healthy Kids in Telemark - a School Based Health Promoting Intervention
|
N/A | |
Not yet recruiting |
NCT02950779 -
Assessment of Handgrip Strength in Adults With Inflammatory Bowel Disease
|
N/A | |
Completed |
NCT02486588 -
Increasing Engagement With a Healthy Food Benefit
|
N/A | |
Withdrawn |
NCT01184027 -
Impact of Nutrition and Swallowing Function of Head and Neck Cancer Patients During the Course of Treatment
|
N/A | |
Completed |
NCT01178398 -
Understanding Fish Consumption Habits During Pregnancy
|
N/A | |
Completed |
NCT01249508 -
Nutrition Labeling Program to Promote Healthy Dietary Patterns
|
N/A | |
Terminated |
NCT00577499 -
Effect of Lubiprostone on Nutritional Status and Pulmonary Function in Adults With Cystic Fibrosis
|
N/A | |
Completed |
NCT00109551 -
Community Trial of Zinc Supplementation on Preschool Child Mortality and Morbidity in Southern Nepal
|
Phase 3 |